{"transactions":[{"id":1071052,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-08T16:06:58.000Z","date":"2025-08-08","kind":"other","planned":false,"acquired":false,"shares":82006,"ownership":{"direct":false,"nature":"By Versant Affiliates Fund V, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares are held by Versant Affiliates Fund V, L.P. (\"Affiliates V\"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021338","document":"form4-08082025_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000141588925021338/form4-08082025_080854.xml","form_type":"4"}},{"id":1071051,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-08T16:06:58.000Z","date":"2025-08-08","kind":"other","planned":false,"acquired":false,"shares":90888,"ownership":{"direct":false,"nature":"By Versant Ophthalmic Affiliates Fund I, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. (\"Ophthalmic\"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021338","document":"form4-08082025_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000141588925021338/form4-08082025_080854.xml","form_type":"4"}},{"id":1071050,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-08T16:06:58.000Z","date":"2025-08-08","kind":"other","planned":false,"acquired":false,"shares":207486,"ownership":{"direct":false,"nature":"By Versant Venture Capital V (Canada) LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by Versant Venture Capital V (Canada) LP (\"Canada V\"). Versant Ventures V (Canada), L.P. (\"Canada V GP\") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. (\"Canada V GP-GP\") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021338","document":"form4-08082025_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000141588925021338/form4-08082025_080854.xml","form_type":"4"}},{"id":1071049,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-08T16:06:58.000Z","date":"2025-08-08","kind":"other","planned":false,"acquired":false,"shares":2726322,"ownership":{"direct":false,"nature":"By Versant Venture Capital V, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Versant Venture Capital V, L.P. (\"Versant V\"). Versant Ventures V, LLC (\"Versant V GP\") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021338","document":"form4-08082025_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000141588925021338/form4-08082025_080854.xml","form_type":"4"}},{"id":1071048,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-08T16:06:58.000Z","date":"2025-08-08","kind":"other","planned":false,"acquired":false,"shares":274990,"ownership":{"direct":false,"nature":"By Versant Vantage II, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Versant Vantage II, L.P. (\"Vantage II\"). Versant Vantage II GP, L.P. (\"Vantage II GP\") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP\") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021338","document":"form4-08082025_080854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000141588925021338/form4-08082025_080854.xml","form_type":"4"}},{"id":1462004,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-02T16:45:07.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":12770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."}],"balance_after":12770,"derivative":{"exercise_price":2.69,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":12770},"source":{"system":"sec-edgar","filing":"0001415889-24-018923","document":"form4-07022024_040704.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000141588924018923/form4-07022024_040704.xml","form_type":"4"}},{"id":1758757,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-17T18:39:57.000Z","date":"2023-10-16","kind":"grant","planned":false,"acquired":true,"shares":25540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the date of the first annual general meeting of stockholders occurring after October 12, 2023, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25540,"derivative":{"exercise_price":2.61,"expiration_date":"2033-10-15","underlying":"Common Stock","underlying_shares":25540},"source":{"system":"sec-edgar","filing":"0001209191-23-053002","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123053002/doc4.xml","form_type":"4"}},{"id":1809770,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:06:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13300,"price":26.12,"value":347396.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":13.88,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001209191-23-045415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045415/doc4.xml","form_type":"4"}},{"id":1809769,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:06:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5948,"price":23.19,"value":137934.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":16.81,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":5948},"source":{"system":"sec-edgar","filing":"0001209191-23-045415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045415/doc4.xml","form_type":"4"}},{"id":1809768,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:06:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23522,"price":25.23,"value":593460.06,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":14.77,"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":23522},"source":{"system":"sec-edgar","filing":"0001209191-23-045415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045415/doc4.xml","form_type":"4"}},{"id":1809767,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T16:06:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":210996,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below).  Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received:  (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a \"CVR\"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the \"Contingent Value Rights Agreement\") entered into concurrent with completion of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Versant Voyageurs I Parallel, L.P. (\"Versant I Parallel\").  Versant Voyageurs I GP, L.P. (\"Versant Voyageurs I GP\") is the general partner of Versant I Parallel.  Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant Voyageurs I GP.  Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP.  Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel.  Each of Jerel C. Davis, Versant Ventures VI GP-GP, Versant Ventures VI GP, and Versant Voyageurs I GP disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-045415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045415/doc4.xml","form_type":"4"}},{"id":1809766,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T16:06:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":719104,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below).  Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received:  (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a \"CVR\"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the \"Contingent Value Rights Agreement\") entered into concurrent with completion of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Voyageurs I, L.P. (\"Versant Voyageurs I\").  Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I.  Jerel C. Davis is a member of the Issuer's board of directors and is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I.  Each of Jerel C. Davis and Versant Voyageurs I GP Company disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-045415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045415/doc4.xml","form_type":"4"}},{"id":1809765,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T16:06:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2105107,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below).  Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received:  (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a \"CVR\"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the \"Contingent Value Rights Agreement\") entered into concurrent with completion of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Venture Capital VII, L.P. (\"Versant VII\").  Versant Ventures VII GP, L.P. (\"Versant Ventures VII GP\") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC (\"Versant Ventures VII GP-GP\") is the general partner of Versant Ventures VII GP.  Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII.  Each of Jerel C. Davis, Versant Ventures VII GP-GP, and Versant Ventures VII GP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-045415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045415/doc4.xml","form_type":"4"}},{"id":1809764,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T16:06:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":447013,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below).  Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received:  (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a \"CVR\"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the \"Contingent Value Rights Agreement\") entered into concurrent with completion of the Merger."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-045415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045415/doc4.xml","form_type":"4"}},{"id":1822024,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":2196402,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Vantage II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Versant Vantage II, L.P. (\"Vantage II\"). Versant Vantage II GP, L.P. (\"Vantage II GP\") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP\") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":274990},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822023,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":33682,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Affiliates Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by Versant Affiliates Fund V, L.P. (\"Affiliates V\"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4216},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822022,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":37283,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Ophthalmic Affiliates Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. (\"Ophthalmic\"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4667},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822021,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":85217,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V (Canada) LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Versant Venture Capital V (Canada) LP (\"Canada V\"). Versant Ventures V (Canada), L.P. (\"Canada V GP\") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. (\"Canada V GP-GP\") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10669},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822020,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":1119729,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Versant Venture Capital V, L.P. (\"Versant V\"). Versant Ventures V, LLC (\"Versant V GP\") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":140190},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822019,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":230117,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Affiliates Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by Versant Affiliates Fund V, L.P. (\"Affiliates V\"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":28810},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822018,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":255081,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Ophthalmic Affiliates Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. (\"Ophthalmic\"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":31936},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822017,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":582206,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V (Canada) LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Versant Venture Capital V (Canada) LP (\"Canada V\"). Versant Ventures V (Canada), L.P. (\"Canada V GP\") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. (\"Canada V GP-GP\") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":72892},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822016,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":7650043,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Versant Venture Capital V, L.P. (\"Versant V\"). Versant Ventures V, LLC (\"Versant V GP\") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":957787},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822015,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":106208,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Affiliates Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by Versant Affiliates Fund V, L.P. (\"Affiliates V\"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13297},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822014,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":117730,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Ophthalmic Affiliates Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. (\"Ophthalmic\"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14739},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822013,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":268711,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V (Canada) LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Versant Venture Capital V (Canada) LP (\"Canada V\"). Versant Ventures V (Canada), L.P. (\"Canada V GP\") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. (\"Canada V GP-GP\") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33642},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822012,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":3530789,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Versant Venture Capital V, L.P. (\"Versant V\"). Versant Ventures V, LLC (\"Versant V GP\") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":442055},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822011,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":237575,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Affiliates Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by Versant Affiliates Fund V, L.P. (\"Affiliates V\"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":29744},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822010,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":263349,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Ophthalmic Affiliates Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. (\"Ophthalmic\"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32971},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822009,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":601077,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V (Canada) LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Versant Venture Capital V (Canada) LP (\"Canada V\"). Versant Ventures V (Canada), L.P. (\"Canada V GP\") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. (\"Canada V GP-GP\") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":75255},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822008,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":false,"shares":7897999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Versant Venture Capital V, L.P. (\"Versant V\"). Versant Ventures V, LLC (\"Versant V GP\") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":988832},"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822007,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"purchase","planned":false,"acquired":true,"shares":5939,"price":12,"value":71268.0,"ownership":{"direct":false,"nature":"By Versant Affiliates Fund V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by Versant Affiliates Fund V, L.P. (\"Affiliates V\"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein."}],"balance_after":82006,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822006,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"purchase","planned":false,"acquired":true,"shares":6575,"price":12,"value":78900.0,"ownership":{"direct":false,"nature":"By Versant Ophthalmic Affiliates Fund I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. (\"Ophthalmic\"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein."}],"balance_after":90888,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822005,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"purchase","planned":false,"acquired":true,"shares":15028,"price":12,"value":180336.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V (Canada) LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Versant Venture Capital V (Canada) LP (\"Canada V\"). Versant Ventures V (Canada), L.P. (\"Canada V GP\") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. (\"Canada V GP-GP\") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":207486,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822004,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"purchase","planned":false,"acquired":true,"shares":197458,"price":12,"value":2369496.0,"ownership":{"direct":false,"nature":"By Versant Venture Capital V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Versant Venture Capital V, L.P. (\"Versant V\"). Versant Ventures V, LLC (\"Versant V GP\") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein."}],"balance_after":2726322,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822003,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":true,"shares":274990,"ownership":{"direct":false,"nature":"By Versant Vantage II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Versant Vantage II, L.P. (\"Vantage II\"). Versant Vantage II GP, L.P. (\"Vantage II GP\") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP\") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":274990,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822002,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":true,"shares":76067,"ownership":{"direct":false,"nature":"By Versant Affiliates Fund V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by Versant Affiliates Fund V, L.P. (\"Affiliates V\"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein."}],"balance_after":76067,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822001,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":true,"shares":84313,"ownership":{"direct":false,"nature":"By Versant Ophthalmic Affiliates Fund I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. (\"Ophthalmic\"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein."}],"balance_after":84313,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1822000,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":true,"shares":192458,"ownership":{"direct":false,"nature":"By Versant Venture Capital V (Canada) LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by Versant Venture Capital V (Canada) LP (\"Canada V\"). Versant Ventures V (Canada), L.P. (\"Canada V GP\") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. (\"Canada V GP-GP\") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein."}],"balance_after":192458,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1821999,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-27T16:21:36.000Z","date":"2023-07-25","kind":"exercise","planned":false,"acquired":true,"shares":2528864,"ownership":{"direct":false,"nature":"By Versant Venture Capital V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Versant Venture Capital V, L.P. (\"Versant V\"). Versant Ventures V, LLC (\"Versant V GP\") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein."}],"balance_after":2528864,"source":{"system":"sec-edgar","filing":"0001209191-23-043525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745958/000120919123043525/doc4.xml","form_type":"4"}},{"id":1824910,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-21T21:07:08.000Z","date":"2023-07-19","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.72,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-043134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919123043134/doc4.xml","form_type":"4"}},{"id":1873255,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-31T19:22:24.000Z","date":"2023-05-26","kind":"exercise","planned":false,"acquired":false,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0001209191-23-033187","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123033187/doc4.xml","form_type":"4"}},{"id":1873254,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T19:22:24.000Z","date":"2023-05-26","kind":"exercise","planned":false,"acquired":true,"shares":3300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":733770,"source":{"system":"sec-edgar","filing":"0001209191-23-033187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123033187/doc4.xml","form_type":"4"}},{"id":1917133,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-19T17:58:40.000Z","date":"2023-04-17","kind":"sale","planned":false,"acquired":false,"shares":295808,"price":20.7507,"value":6138223.0656,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an arrangement between the Reporting Person and Versant Venture Management, LLC (\"VVM\"), the sale of these securities was executed by VVM on behalf of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.75 to $20.97, inclusive. The Reporting Person and VVM undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":443713,"source":{"system":"sec-edgar","filing":"0000899243-23-011458","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924323011458/doc4.xml","form_type":"4"}},{"id":1972861,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-03T16:13:06.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":36751,"price":22.75,"value":836085.25,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Versant Voyageurs I Parallel, L.P. (\"Versant I Parallel\"). Versant Voyageurs I GP, L.P. (\"Versant Voyageurs I GP\") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein."}],"balance_after":210996,"source":{"system":"sec-edgar","filing":"0000899243-23-006968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924323006968/doc4.xml","form_type":"4"}},{"id":1972860,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-03T16:13:06.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":123249,"price":22.75,"value":2803914.75,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Voyageurs I, L.P. (\"Versant Voyageurs I\"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and the Reporting Person disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein."}],"balance_after":719104,"source":{"system":"sec-edgar","filing":"0000899243-23-006968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924323006968/doc4.xml","form_type":"4"}},{"id":1972859,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-03T16:13:06.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":240000,"price":22.75,"value":5460000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Versant Venture Capital VII, L.P. (\"Versant VII\"). Versant Ventures VII GP, L.P. (\"Versant Ventures VII GP\") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC (\"Versant Ventures VII GP-GP\") is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein."}],"balance_after":2105107,"source":{"system":"sec-edgar","filing":"0000899243-23-006968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924323006968/doc4.xml","form_type":"4"}},{"id":2072775,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":true,"shares":3014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F18","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada)."}],"balance_after":25131,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072774,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":false,"shares":4721,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F17","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072773,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":true,"shares":4721,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F15","text":"Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein."}],"balance_after":4721,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072772,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":false,"shares":21854,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP (\"VVC V (Canada)\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. (\"VV V (Canada) GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V (Canada)\") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein."}],"balance_after":42877,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072771,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":true,"shares":1240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V."}],"balance_after":22117,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072770,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":false,"shares":65957,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072769,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":true,"shares":2065,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":65957,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072768,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":false,"shares":9561,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOAF I\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein."}],"balance_after":18761,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072767,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":true,"shares":1866,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":63892,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072766,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":false,"shares":8638,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. (\"VAF V\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein."}],"balance_after":16949,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072765,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":true,"shares":62026,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":62026,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2072764,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-01-03T21:38:20.000Z","date":"2022-12-29","kind":"other","acquired":false,"shares":287157,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. (\"VVC V\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by VVC V. Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein."}],"balance_after":563403,"source":{"system":"sec-edgar","filing":"0000899243-23-000260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924323000260/doc4.xml","form_type":"4"}},{"id":2076085,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-27T17:42:16.000Z","date":"2022-12-22","kind":"other","acquired":true,"shares":1646,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents a change in the form of ownership of the Reporting Person as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I."}],"balance_after":739521,"source":{"system":"sec-edgar","filing":"0000899243-22-039387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322039387/doc4.xml","form_type":"4"}},{"id":2076084,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-27T17:42:16.000Z","date":"2022-12-22","kind":"other","acquired":false,"shares":9465,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP, to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-039387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322039387/doc4.xml","form_type":"4"}},{"id":2076083,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-27T17:42:16.000Z","date":"2022-12-22","kind":"other","acquired":true,"shares":5865,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a change in the form of ownership of Versant Voyageurs I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":9465,"source":{"system":"sec-edgar","filing":"0000899243-22-039387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322039387/doc4.xml","form_type":"4"}},{"id":2076082,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-27T17:42:16.000Z","date":"2022-12-22","kind":"other","acquired":false,"shares":108715,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. (\"Versant I Parallel\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by Versant I Parallel. Versant Voyageurs I GP is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein."}],"balance_after":247747,"source":{"system":"sec-edgar","filing":"0000899243-22-039387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322039387/doc4.xml","form_type":"4"}},{"id":2076081,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-27T17:42:16.000Z","date":"2022-12-22","kind":"other","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. (\"Versant Voyageurs I GP\") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":3600,"source":{"system":"sec-edgar","filing":"0000899243-22-039387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322039387/doc4.xml","form_type":"4"}},{"id":2076080,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-27T17:42:16.000Z","date":"2022-12-22","kind":"other","acquired":false,"shares":364587,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. (\"Versant Voyageurs I\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Voyageurs I. Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and the Reporting Person disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein."}],"balance_after":842353,"source":{"system":"sec-edgar","filing":"0000899243-22-039387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322039387/doc4.xml","form_type":"4"}},{"id":2088210,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-12-13T21:18:41.000Z","date":"2022-12-09","kind":"sale","acquired":false,"shares":250000,"price":16,"value":4000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP-GP, LLC (\"VV VI GP\") is the sole general partner of Versant Ventures VI GP, L.P. (\"VV VI\") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein."}],"balance_after":2094451,"source":{"system":"sec-edgar","filing":"0000899243-22-038311","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322038311/doc4.xml","form_type":"4"}},{"id":2159271,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":false,"shares":9384,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F18","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP-GP to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"Shares held by Versant Ventures VII GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159270,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":true,"shares":9384,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"Represents a change in the form of ownership of Versant Ventures VII GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"Shares held by Versant Ventures VII GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":9384,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159269,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":true,"shares":1975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F15","text":"Represents a change in the form of ownership of the Reporting Person as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP."}],"balance_after":737875,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159268,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":false,"shares":11359,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP; however, each of Versant Ventures VII GP-GP and the Reporting Person disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159267,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":true,"shares":11359,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. (\"Versant Ventures VII GP\") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC (\"Versant Ventures VII GP-GP\") is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP; however, each of Versant Ventures VII GP-GP and the Reporting Person disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein."}],"balance_after":11359,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159266,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":false,"shares":567963,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VII, L.P. (\"Versant VII\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. (\"Versant Ventures VII GP\") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC (\"Versant Ventures VII GP-GP\") is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein."}],"balance_after":2345107,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159265,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":true,"shares":1316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents a change in the form of ownership of the Reporting Person as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Voyageurs I."}],"balance_after":735900,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159264,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":false,"shares":7570,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP, to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159263,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":true,"shares":4692,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a change in the form of ownership of Versant Voyageurs I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":7570,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159262,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":false,"shares":86972,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. (\"Versant I Parallel\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by Versant I Parallel. Versant Voyageurs I GP is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein."}],"balance_after":356462,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159261,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":true,"shares":2878,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. (\"Versant Voyageurs I GP\") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":2878,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2159260,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-14T16:53:09.000Z","date":"2022-09-12","kind":"other","acquired":false,"shares":291670,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. (\"Versant Voyageurs I\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Voyageurs I. Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and the Reporting Person disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein."}],"balance_after":1206940,"source":{"system":"sec-edgar","filing":"0000899243-22-031052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322031052/doc4.xml","form_type":"4"}},{"id":2184068,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-16T16:44:27.000Z","date":"2022-08-12","kind":"other","acquired":true,"shares":1646,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents a change in the form of ownership of the Reporting Person as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I."}],"balance_after":734584,"source":{"system":"sec-edgar","filing":"0000899243-22-028805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322028805/doc4.xml","form_type":"4"}},{"id":2184067,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-16T16:44:27.000Z","date":"2022-08-12","kind":"other","acquired":false,"shares":9466,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP, to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322028805/doc4.xml","form_type":"4"}},{"id":2184066,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-16T16:44:27.000Z","date":"2022-08-12","kind":"other","acquired":true,"shares":5866,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a change in the form of ownership of Versant Voyageurs I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":9466,"source":{"system":"sec-edgar","filing":"0000899243-22-028805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322028805/doc4.xml","form_type":"4"}},{"id":2184065,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-16T16:44:27.000Z","date":"2022-08-12","kind":"other","acquired":false,"shares":108715,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. (\"Versant I Parallel\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by Versant I Parallel. Versant Voyageurs I GP is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein."}],"balance_after":443434,"source":{"system":"sec-edgar","filing":"0000899243-22-028805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322028805/doc4.xml","form_type":"4"}},{"id":2184064,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-16T16:44:27.000Z","date":"2022-08-12","kind":"other","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. (\"Versant Voyageurs I GP\") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Voyageurs I GP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein."}],"balance_after":3600,"source":{"system":"sec-edgar","filing":"0000899243-22-028805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322028805/doc4.xml","form_type":"4"}},{"id":2184063,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-16T16:44:27.000Z","date":"2022-08-12","kind":"other","acquired":false,"shares":364587,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. (\"Versant Voyageurs I\") to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Versant Voyageurs I. Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and the Reporting Person disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein."}],"balance_after":1498610,"source":{"system":"sec-edgar","filing":"0000899243-22-028805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000089924322028805/doc4.xml","form_type":"4"}},{"id":2224266,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T21:37:26.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.54,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919122038732/doc4.xml","form_type":"4"}},{"id":2240316,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":true,"shares":6448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F20","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada)."}],"balance_after":20877,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240315,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":false,"shares":10099,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F19","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240314,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":true,"shares":10099,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F17","text":"Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein."}],"balance_after":10099,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240313,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":false,"shares":46753,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V (Canada) to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Versant Venture Capital V (Canada) LP (\"VVC V (Canada)\"). Versant Ventures V (Canada) GP-GP, Inc. (\"VV V (Canada) GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V (Canada)\") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein."}],"balance_after":64731,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240312,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":true,"shares":2653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F15","text":"Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V."}],"balance_after":14429,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240311,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":false,"shares":141103,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F14","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240310,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":true,"shares":4419,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":141103,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240309,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":false,"shares":20454,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VOAF I to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOAF I\"). VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein."}],"balance_after":28322,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240308,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":true,"shares":3992,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":136684,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240307,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":false,"shares":18478,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VAF V to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Affiliates Fund V, L.P. (\"VAF V\"). VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein."}],"balance_after":25587,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240306,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":true,"shares":132692,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":132692,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240305,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-06","kind":"other","acquired":false,"shares":614315,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Versant Venture Capital V, L.P. (\"VVC V\"). Versant Ventures V, LLC (\"VV V\") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein."}],"balance_after":850560,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240304,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":33395,"price":12.2517,"value":409145.5215,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Versant Venture Capital V (Canada) LP (\"VVC V (Canada)\"). Versant Ventures V (Canada) GP-GP, Inc. (\"VV V (Canada) GP\") is the sole general partner of Versant Ventures V (Canada), L.P. (\"VV V (Canada)\") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein."}],"balance_after":111484,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240303,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":14611,"price":12.2517,"value":179009.5887,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by Versant Ophthalmic Affiliates Fund I, L.P. (\"VOAF I\"). VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein."}],"balance_after":48776,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}},{"id":2240302,"issuer":{"id":68433,"kind":"organization","name":"Repare Therapeutics Inc.","symbol":"RPTX"},"owners":[{"id":76748,"kind":"person","name":"Jerel Davis","position":1,"cik":"0001745958","reported_name":"Jerel Davis","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-06-07T20:32:00.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":13199,"price":12.2517,"value":161710.1883,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by Versant Affiliates Fund V, L.P. (\"VAF V\"). VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein."}],"balance_after":44065,"source":{"system":"sec-edgar","filing":"0000899243-22-021345","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808158/000089924322021345/doc4.xml","form_type":"4"}}],"next_cursor":"2022-06-07T20:32:00.000000Z,2240302"}